Inventor · disambiguated record
Mario Mautino
Also filed as: MAUTINO MARIO · MAUTINO MARIO R
19 granted patents·7 pending applications·70 citations·filing 2003–2023
93Inventor score
Top patents by PatentIndex Score
26 records- 0192US9617272B2Tricyclic compounds as inhibitors of immunosuppression mediated by tryptophan metabolizationNEWLINK GENETICS CORP·Filed 2014·Granted Apr 11, 2017·21 cites·43 claims
- 0290US9260434B2Fused imidazole derivatives useful as IDO inhibitorsNEWLINK GENETICS CORP·Filed 2013·Granted Feb 16, 2016·11 cites·29 claims
- 0389US10233190B2IDO inhibitorsNEWLINK GENETICS CORP·Filed 2017·Granted Mar 19, 2019·6 cites·20 claims
- 0489US7998486B2Enhanced immunogenicity of tumor associated antigens by addition of alphaGal epitopesNEWLINK GENETICS CORP·Filed 2007·Granted Aug 16, 2011·5 cites·9 claims
- 0587US9388191B2Fused imidazole derivatives useful as IDO inhibitorsNEWLINK GENETICS CORP·Filed 2015·Granted Jul 12, 2016·5 cites·26 claims
- 0686US9732035B2Salts and prodrugs of 1-methyl-D-tryptophanNEWLINK GENETICS CORP·Filed 2016·Granted Aug 15, 2017·5 cites·30 claims
- 0781US8748469B2IDO inhibitorsMAUTINO MARIO R·Filed 2009·Granted Jun 10, 2014·6 cites·7 claims
- 0879US9090643B2Enhanced immunogenicity of tumor associated antigens by addition of alphagal epitopesNEWLINK GENETICS CORP·Filed 2012·Granted Jul 28, 2015·1 cites·4 claims
- 0979US8916169B2Enhanced immunogenicity of tumor associated antigens by addition of alphagal epitopesNEWLINK GENETICS CORP·Filed 2012·Granted Dec 23, 2014·1 cites·1 claims
- 1075US10207990B2Salts and prodrugs of 1-methyl-D-tryptophanNEWLINK GENETICS CORP·Filed 2017·Granted Feb 19, 2019·1 cites·27 claims
- 1174US9850248B2IDO inhibitorsNEWLINK GENETICS CORP·Filed 2016·Granted Dec 26, 2017·1 cites·36 claims
- 1274US9174942B2IDO inhibitorsNEWLINK GENETICS CORP·Filed 2014·Granted Nov 3, 2015·2 cites·19 claims
- 1373US8722720B2Imidazole derivatives as IDO inhibitorsMAUTINO MARIO R·Filed 2010·Granted May 13, 2014·2 cites·15 claims
- 1472US9981973B2Tricyclic compounds as inhibitors of immunosuppression mediated by tryptophan metabolizationNEWLINK GENETICS CORP·Filed 2017·Granted May 29, 2018·1 cites·38 claims
- 1569US11485705B2Salts and prodrugs of 1-methyl-d-tryptophanLUMOS PHARMA INC·Filed 2020·Granted Nov 1, 2022·0 cites·20 claims
- 1666US9512158B2Enhanced immunogenicity of tumor associated antigens by addition of alphagal epitopesNEWLINK GENETICS CORP·Filed 2012·Granted Dec 6, 2016·0 cites·9 claims
- 1765US8357777B2Enhanced immunogenicity of tumor associated antigens by addition of αgal epitopesNEWLINK GENETICS·Filed 2011·Granted Jan 22, 2013·1 cites·1 claims
- 1861US7078179B2Selectable gene marker system based on expression of N-acetyllactosaminide 3-α galactosyltransferaseNEWLINK GENETICS CORP·Filed 2004·Granted Jul 18, 2006·1 cites·34 claims
- 1960US2019248739A1Salts and prodrugs of 1-methyl-d-tryptophanNEWLINK GENETICS CORP·Filed 2019·Application pending·0 cites
- 2057US2019225618A1IDO InhibitorsMAUTINO MARIO·Filed 2019·Application pending·0 cites
- 2157US2023404642A1Method for the treatment of cancer via tumor cell lysis and intratumoral administration of combinations of immunotherapeutic ingredientsSYNCROMUNE INC·Filed 2023·Application pending·0 cites
- 2251US2016022826A1Carbohydrate-modified glycoproteins and uses thereofNEWLINK GENETICS CORP·Filed 2014·Application pending·0 cites
- 2349US10047066B2IDO inhibitorsMAUTINO MARIO·Filed 2008·Granted Aug 14, 2018·0 cites·1 claims
- 2446US2013149331A1Rhamnose and forssman conjugated immunogenic agentsWANG PENG GEORGE·Filed 2012·Application pending·0 cites
- 2545US2013289083A1IDO InhibitorsNEWLINK GENETICS CORP·Filed 2013·Application pending·0 cites
- 2644US2006134629A1Methods and compositions for elucidating protein expression profiles in cellsLINK CHARLES J·Filed 2003·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Mario Mautino files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →